The January performances of the 37 stocks within the fledgling but burgeoning psychedelic bio-pharmaceutical drug stocks sector.

The huge dollar totals here are only half the story. Equally important is the progress in raising capital for individual companies.

Below is the latest news and stock prices for each of 30 companies operating in the fledgling but burgeoning psychedelic bio-pharmaceutical drug sector from the beginning of 2021 to date.

With its first psychedelic-assisted treatment clinic preparing to open, Mind Cure Health is an undervalued rotation target.

$400 million in investment capital has flooded into psychedelic drug companies in just the last 10 weeks. Investors take note.